Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others) and by Region (North America, Latin Amer

Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Viscosupplementation is a treatment that helps in reducing the joint pain, and improves the functional condition of the osteoarthritic joint. It involves the injection of a thick fluid called hyaluronic acid into the knee. Hyaluronic acid (HA) is found in the synovial fluid that lubricates the cartilage surfaces and protects the joints from shock. HA is an elastic substance naturally secreted by mesothelial cells. Osteoarthritis is the most common type of arthritis characterized by loss of function and degeneration of cartilage and tissues that cover the ends of the bones in a joint.
Market Dynamics
Rising prevalence of osteoarthritis such as knee osteoarthritis, hip osteoarthritis, tennis elbow, joint pain and others are orthopedic disorders that are expected to augment the global viscosupplementation market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), osteoarthritis (OA) is the most common joint disorder in the U.S. For instance, from 2013- 2015, on an annual basis, an estimated 54.4 million adults in the U.S. were diagnosed with osteoarthritis, among which 7.1% were in the age group of 18 to 44 years, 29.3% people were aged between 45 to 64 years, and 49.6% people were in the age group of 65 years or older.
Increasing adoption of inorganic strategies such as collaborations and partnerships by manufacturers is expected to drive the global viscosupplementation market growth over the forecast period.
Manufactures are engaged in adopting strategies such as collaborations and partnership agreements in order to expand their distribution network and carry out production, research and development activities to produce new innovative products in the market. For instance, in May 2016, Anika Therapeutics formed a commercialization partnership with Pendopharm, a division of Pharmascience Inc., to sell Anika Therapeutics' product CINGAL, in Canada.
Key features of the study:
This report provides in-depth analysis of the global viscosupplementation market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global viscosupplementation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, end user upgrades, market expansion, and marketing tactics
The global viscosupplementation market report caters to various stakeholders in this industry, including investors, device/system manufacturers, distributors and suppliers for viscosupplimentation products, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the viscosupplementation market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation
Global Viscosupplementation Market, By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
Global Viscosupplementation Market, By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
Global Viscosupplementation Market, By Region:
North America
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country:
U.S.
Canada
Europe
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Latin America
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Asia Pacific
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment:
Single Injection Treatment Cycle
Three Injection Treatment Cycle
Five Injection Treatment Cycle
By Application:
Knee Osteoarthritis
Hip Osteoarthritis
Others
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Anika Therapeutics Inc*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Strategies
Seikagaku Corporation
Ferring Pharmaceuticals
Bioventus
Fidia Farmaceutici S.P.A.
Mylan N.V.
Sanofi S.A.
ORTHOGENRX
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson

“*” marked represents similar segmentation in other categories in the respective section.